Covalon Technologies Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA22282D3022
CAD
1.97
0.02 (1.03%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Covalon Technologies Ltd. stock-summary
stock-summary
Covalon Technologies Ltd.
Pharmaceuticals & Biotechnology
Covalon Technologies Ltd. is a researcher, developer, manufacturer and marketer of medical products that manage patient outcomes and save lives in the areas of wound care, infection management and surgical procedures. The Company offers platform technologies: Collagen matrix; Antimicrobial silicone adhesive and Medical coating technology. The collagen matrix platform is used to manufacture products that treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns. The antimicrobial silicone adhesive platform is the basis for a range of pre-surgical, post surgical and vascular access products that are designed to kill any bacteria or yeast that comes into contact with the antimicrobial silicone. The coating technology is a grafting from process, which utilizes photo-polymerization to create active grafting sites.
Company Coordinates stock-summary
Company Details
1660 Tech Ave Unit 5 , MISSISSAUGA ON : L4W 5S7
stock-summary
Tel: 1 905 5688400
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Amir Boloor
Chairman of the Board
Brian Pedlar
President, Chief Executive Officer, Director
Hon. Elinor Caplan
Director
Maj. Gen. (Retd.) Gale Pollock
Director
Mr. Ronald Smith
Director
John Suk
Director
Dr. Ian Brindle
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 60 Million (Micro Cap)

stock-summary
P/E

24.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.59

stock-summary
Return on Equity

8.30%

stock-summary
Price to Book

2.01